Clinical Trial Update: UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) [Phase 4]

View source ↗

Summary

This Phase 4 trial update compares ranibizumab and aflibercept to study systemic anti-VEGF effects in neovascular age-related macular degeneration, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovacular Age-related Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2017-02-28